Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2012 | 12-2011 | 09-2011 | 06-2011 | 03-2011 | |
| Sales | 13,913,000 | 14,996,000 | 15,034,000 | 15,123,000 | 14,222,000 |
| Cost of Goods | 4,484,000 | 5,118,000 | 4,788,000 | 4,619,000 | 4,458,000 |
| Gross Profit | 9,429,000 | 9,878,000 | 10,246,000 | 10,504,000 | 9,764,000 |
| Operating Expenses | 6,693,000 | 8,779,000 | 7,295,000 | 7,182,000 | 6,356,000 |
| Operating Income | 2,736,000 | 1,099,000 | 2,951,000 | 3,322,000 | 3,408,000 |
| Interest Expense | 164,000 | 174,000 | 198,000 | 190,000 | 189,000 |
| Other Income | 87,000 | 118,000 | 155,000 | 114,000 | 139,000 |
| Pre-tax Income | 2,659,000 | 1,043,000 | 2,908,000 | 3,246,000 | 3,358,000 |
| Income Tax | 390,000 | 6,000 | 420,000 | 520,000 | 537,000 |
| Net Income Continuous | 2,269,000 | 1,037,000 | 2,488,000 | 2,726,000 | 2,821,000 |
| Minority Interests | 22,000 | 35,000 | 24,000 | 22,000 | 51,000 |
| Net Income | $2,247,000 | $1,002,000 | $2,464,000 | $2,704,000 | $2,770,000 |
| EPS Basic Total Ops | 0.93 | 0.39 | 1.02 | 1.13 | 1.21 |
| EPS Basic Continuous Ops | 0.94 | 0.41 | 1.03 | 1.14 | 1.23 |
| EPS Diluted Total Ops | 0.92 | 0.38 | 1.01 | 1.11 | 1.20 |
| EPS Diluted Continuous Ops | 0.93 | 0.40 | 1.02 | 1.12 | 1.22 |
| EBITDA(a) | $3,880,000 | $3,063,000 | $4,379,000 | $4,705,000 | $4,613,000 |